AR035909A1 - Esteres de derivados de adenosina n6-oxa, -tia, -tioxa, y azacicloalquilo sustituidos, composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de un medicamento - Google Patents
Esteres de derivados de adenosina n6-oxa, -tia, -tioxa, y azacicloalquilo sustituidos, composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de un medicamentoInfo
- Publication number
- AR035909A1 AR035909A1 ARP000102555A ARP000102555A AR035909A1 AR 035909 A1 AR035909 A1 AR 035909A1 AR P000102555 A ARP000102555 A AR P000102555A AR P000102555 A ARP000102555 A AR P000102555A AR 035909 A1 AR035909 A1 AR 035909A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- heterocyclyl
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Un compuesto derivado de adenosina, una composición farmacéutica para utilizar la composición como un agonista del receptor de adenosina A1; uso de una cantidad terapéuticamente efectiva de la composición que es para la manufactura de un medicamento para estimular la actividad coronaria en una mamífero que experimenta un trastorno eléctrico coronario que puede ser tratado estimulando un receptor de adenosina A. Reivindicación 1: Esteres derivados de adenosina N6-oxa, -tia, -tioxa y azacicloalquilo sustituidos, caracterizado porque tiene la fórmula (1). en donde R1 es un grupo monocíclico o policíclico heterocíclico que contiene entre 3 y 15 átomos, por lo menos uno de los cuales se selecciona entre el grupo que consiste en N, O, P y S-(O)0-2 y en donde R1 no contiene un grupo epóxido, y en donde R2, R2' y R2'' son seleccionados independientemente entre el grupo que consiste en alquilo C1-15, alquenilo C2-15, alquinilo C2-15, heterociclilo, arilo y heteroarilo, dicho alquilo, alquenilo, alquinilo, arilo, heterociclilo y heteroarilo son optativamente sustituidos con 1 a 3 sustituyentes seleccionados independientemente entre el grupo de halo, NO2, heterociclilo, arilo, heteroarilo, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, C(O)OCH2OC(O)R20 y OCON(R20)2 y cada sustituyente heteroarilo, arilo y heterociclilo opcional es optativamente sustituido con halo, NO2, alquilo, CF3, amino, mono- o di-alquilamino, alquilo o arilo o heteroarilamida, NCOR22, NR20SO2R22, COR20, CO2R20, CON(R20)2, NR20CON(R20)2, OC(O)R20, OC(O)N(R20)2, SR20, S(O)R22, SO2R22, SO2N(R20)2, CN o OR20; en donde R20 es un miembro seleccionado entre el grupo que consiste en H, alquilo C1-15, alquenilo C2-15, alquinilo C2-15, heterociclilo, arilo y heteroarilo, dicho alquilo, alquenilo, alquinilo, heterociclilo, arilo y heteroarilo son optativamente sustituidos con 1 a 3 sustituyentes seleccionados independientemente de halo, alquilo, mono- o dialquilamino, alquilo o arilo o heteroarilamida, CN, O-alquilo C1-6, CF3, arilo y heteroarilo, y R22 es un miembro seleccionado entre el grupo que consiste en alquilo C1-15, alquenilo C2-15, alquinilo C2-15, heterociclilo, arilo y heteroarilo, dicho alquilo, alquenilo, alquinilo, heterociclilo, arilo y heteroarilo son optativamente sustituidos con 1 a 3 sustituyentes seleccionados independientemente de halo, alquilo, mono- o dialquilamino, alquilo o arilo o heteroarilamida, CN, O-alquilo C1-6, CF3, arilo y heteroarilo,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/317,523 US6576619B2 (en) | 1999-05-24 | 1999-05-24 | Orally active A1 adenosine receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035909A1 true AR035909A1 (es) | 2004-07-28 |
Family
ID=23234062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102555A AR035909A1 (es) | 1999-05-24 | 2000-05-24 | Esteres de derivados de adenosina n6-oxa, -tia, -tioxa, y azacicloalquilo sustituidos, composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de un medicamento |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6576619B2 (es) |
| EP (1) | EP1181302B1 (es) |
| JP (2) | JP2003520776A (es) |
| KR (1) | KR100537032B1 (es) |
| CN (1) | CN1183153C (es) |
| AR (1) | AR035909A1 (es) |
| AT (1) | ATE250621T1 (es) |
| AU (1) | AU760658B2 (es) |
| BR (1) | BR0010882A (es) |
| CA (1) | CA2375040C (es) |
| DE (1) | DE60005507T2 (es) |
| ES (1) | ES2206238T3 (es) |
| IL (2) | IL146471A0 (es) |
| MX (1) | MXPA01012038A (es) |
| NO (1) | NO320854B1 (es) |
| NZ (1) | NZ515580A (es) |
| TW (1) | TW593330B (es) |
| WO (1) | WO2000071558A1 (es) |
| ZA (1) | ZA200109626B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790839B2 (en) | 1999-01-07 | 2004-09-14 | Can-Fite Biopharma Ltd. | Pharmaceutical administration of adenosine agonists |
| IL127947A0 (en) | 1999-01-07 | 1999-11-30 | Can Fite Technologies Ltd | Pharmaceutical use of adenosine agonists |
| EP1476455A1 (en) * | 2002-02-19 | 2004-11-17 | Cv Therapeutics, Inc. | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS |
| DE60326709D1 (de) * | 2002-04-29 | 2009-04-30 | Supernus Pharmaceuticals Inc | Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit |
| JP4771956B2 (ja) | 2003-11-04 | 2011-09-14 | スパーナス ファーマシューティカルズ インコーポレイテッド | バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物 |
| EP1680110B1 (en) * | 2003-11-04 | 2011-01-05 | Supernus Pharmaceuticals, Inc. | Once daily dosage forms of trospium |
| US7820811B2 (en) | 2006-06-27 | 2010-10-26 | Cbt Development Limited | Pro-drugs of adenosine receptor agonists |
| US7731604B2 (en) * | 2006-10-31 | 2010-06-08 | Taylor Made Golf Company, Inc. | Golf club iron head |
| CN101712709A (zh) * | 2008-10-06 | 2010-05-26 | 中国医学科学院药物研究所 | 三乙酰基-3-羟基苯基腺苷及其调血脂的用途 |
| DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460929A1 (de) | 1974-12-21 | 1976-06-24 | Boehringer Sohn Ingelheim | Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung |
| US4364922A (en) | 1980-10-14 | 1982-12-21 | University Of Virginia Alumni Patents Foundation | Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances |
| JPS57171998A (en) | 1981-04-15 | 1982-10-22 | Fujisawa Pharmaceut Co Ltd | Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same |
| DE3138397A1 (de) | 1981-09-26 | 1983-04-07 | Hoechst Ag, 6230 Frankfurt | "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen" |
| CA1255297A (en) | 1984-10-26 | 1989-06-06 | Bharat Trivedi | N.sup.6-benzopyrano and benzothiopyrano adenosines |
| US4593019A (en) | 1984-10-26 | 1986-06-03 | Warner-Lambert Company | N6 -tricyclic adenosines |
| WO1988003148A2 (en) | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Heteroaromatic derivatives of adenoside |
| US4954504A (en) | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
| ZA888083B (en) * | 1987-10-28 | 1990-06-27 | Pro Neuron Inc | Acyl deoxyribonucleoside derivatives and uses thereof |
| US4980379A (en) | 1988-06-30 | 1990-12-25 | The University Of Virginia | Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse |
| DE3843117A1 (de) | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| AU626983B2 (en) | 1989-01-31 | 1992-08-13 | Whitby Research, Inc. | N6-substituted 9-methyladenines |
| US5017578A (en) | 1989-06-09 | 1991-05-21 | Hoechst-Roussel Pharmaceuticals Inc. | N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents |
| JPH06102662B2 (ja) | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| US5432164A (en) | 1991-10-24 | 1995-07-11 | Novo Nordisk A/S | C2,N6 -disubstituted adenosine derivatives |
| DE4205306B4 (de) | 1992-02-21 | 2005-11-24 | Glüsenkamp, Karl-Heinz, Dr. | Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden |
| US5288721A (en) | 1992-09-22 | 1994-02-22 | Cell Therapeutics, Inc. | Substituted epoxyalkyl xanthines |
| WO1994016702A1 (en) | 1993-01-26 | 1994-08-04 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for irregular bowel movement |
| EP0708781B1 (en) | 1993-07-13 | 2001-10-04 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services | A 3 adenosine receptor agonists |
| US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
| US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| GB9723566D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
-
1999
- 1999-05-24 US US09/317,523 patent/US6576619B2/en not_active Expired - Lifetime
-
2000
- 2000-05-19 DE DE60005507T patent/DE60005507T2/de not_active Expired - Lifetime
- 2000-05-19 CA CA002375040A patent/CA2375040C/en not_active Expired - Fee Related
- 2000-05-19 WO PCT/US2000/014036 patent/WO2000071558A1/en active IP Right Grant
- 2000-05-19 NZ NZ515580A patent/NZ515580A/en not_active IP Right Cessation
- 2000-05-19 EP EP00932688A patent/EP1181302B1/en not_active Expired - Lifetime
- 2000-05-19 MX MXPA01012038A patent/MXPA01012038A/es active IP Right Grant
- 2000-05-19 AU AU50376/00A patent/AU760658B2/en not_active Ceased
- 2000-05-19 JP JP2001511301A patent/JP2003520776A/ja active Pending
- 2000-05-19 KR KR10-2001-7015044A patent/KR100537032B1/ko not_active IP Right Cessation
- 2000-05-19 AT AT00932688T patent/ATE250621T1/de not_active IP Right Cessation
- 2000-05-19 ES ES00932688T patent/ES2206238T3/es not_active Expired - Lifetime
- 2000-05-19 IL IL14647100A patent/IL146471A0/xx active IP Right Grant
- 2000-05-19 BR BR0010882-0A patent/BR0010882A/pt not_active Application Discontinuation
- 2000-05-19 CN CNB008080658A patent/CN1183153C/zh not_active Expired - Fee Related
- 2000-05-24 AR ARP000102555A patent/AR035909A1/es active IP Right Grant
- 2000-07-14 TW TW089110048A patent/TW593330B/zh not_active IP Right Cessation
-
2001
- 2001-11-13 IL IL146471A patent/IL146471A/en not_active IP Right Cessation
- 2001-11-20 NO NO20015662A patent/NO320854B1/no not_active IP Right Cessation
- 2001-11-22 ZA ZA200109626A patent/ZA200109626B/en unknown
-
2006
- 2006-07-31 JP JP2006207713A patent/JP2006348040A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU5037600A (en) | 2000-12-12 |
| TW593330B (en) | 2004-06-21 |
| JP2006348040A (ja) | 2006-12-28 |
| NO20015662D0 (no) | 2001-11-20 |
| DE60005507D1 (de) | 2003-10-30 |
| CA2375040C (en) | 2006-02-07 |
| US6576619B2 (en) | 2003-06-10 |
| WO2000071558A1 (en) | 2000-11-30 |
| US20020091099A1 (en) | 2002-07-11 |
| KR100537032B1 (ko) | 2005-12-16 |
| CN1390228A (zh) | 2003-01-08 |
| BR0010882A (pt) | 2002-06-11 |
| KR20020092777A (ko) | 2002-12-12 |
| IL146471A (en) | 2007-06-03 |
| ZA200109626B (en) | 2004-03-10 |
| EP1181302B1 (en) | 2003-09-24 |
| EP1181302A1 (en) | 2002-02-27 |
| CA2375040A1 (en) | 2000-11-30 |
| DE60005507T2 (de) | 2004-06-24 |
| NO20015662L (no) | 2002-01-23 |
| MXPA01012038A (es) | 2002-05-06 |
| NO320854B1 (no) | 2006-02-06 |
| JP2003520776A (ja) | 2003-07-08 |
| AU760658B2 (en) | 2003-05-22 |
| CN1183153C (zh) | 2005-01-05 |
| ATE250621T1 (de) | 2003-10-15 |
| NZ515580A (en) | 2004-06-25 |
| IL146471A0 (en) | 2002-07-25 |
| ES2206238T3 (es) | 2004-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033794A1 (es) | Compuestos de 2-adenosina c-pirazol como agonistas del receptor a2a, uso de los mismos para la manufactura de un medicamento, y composiciones farmaceuticas que los comprenden | |
| PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
| RU95106649A (ru) | Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция | |
| PE1591A1 (es) | Procedimiento para la preparacion de agentes tiazoles antifungicos | |
| BRPI0313942C1 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| ECSP941156A (es) | 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines | |
| KR920011489A (ko) | 세로토닌 길항제 | |
| GT200000107A (es) | Procedimiento para la obtencion de "compuestos de indazol y composiciones farmaceuticas para inhibir las quinasas deproteina y metodos para su uso". | |
| GT200000002A (es) | Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase. | |
| UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| SE7910501L (sv) | Lekemedel for behandling av det centrala nervsystemet | |
| AR035909A1 (es) | Esteres de derivados de adenosina n6-oxa, -tia, -tioxa, y azacicloalquilo sustituidos, composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de un medicamento | |
| PE20010544A1 (es) | Derivados de mutilina utiles como agentes antibacterianos | |
| ES2189330T3 (es) | Derivados heterociclicos n6 de la adenosina sustituidos. | |
| PE59399A1 (es) | Compuestos heterociclicos, composiciones farmaceuticas que los comprenden y metodos para inhibir la liberacion del peptido � - amiloide y/o su sintesis mediante el uso de dichos compuestos | |
| EA200100135A1 (ru) | Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| UY28150A1 (es) | Agentes terapeuticos | |
| ES2154262T3 (es) | Uso de compuestos macrolidos para enfermedades oculares. | |
| AR024634A1 (es) | Composicion farmaceutica estabilizada en forma liofilizada | |
| ES2179353T3 (es) | Antagonistas muscarinicos. | |
| ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
| AR029373A1 (es) | Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |